Article
Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy.
Atherosclerosis - 1 Sept 2005
Yao Q, Nordfors L, Axelsson J, Heimbürger O, Qureshi A R, Báràny P, Lindholm B, Lönnqvist F, Schalling M, Stenvinkel P
Abstract excerpt
BACKGROUND: Inflammation may contribute to the markedly increased cardiovascular morbidity and mortality in end-stage renal disease (ESRD). However, the prevalence of inflammation varies in different ESRD populations. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is an important nuclear signaling protein that may regulate inflammatory response, and recent studies have revealed genetic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.